Relevant literature

De Jong et al. 2016, PLOS Biology describes the HexaBody platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PDF versions of the supplemental figures can be downloaded here.

A comprehensive overview on complement in therapy and disease is described by Melis et al., 2015, Molecular Immunology.

The molecular requirements for IgG-complement interaction and the formation of antibody hexamers upon target binding are described by Diebolder et al., 2014, Science.

Read about Genmab’s passion for innovation and the resulting development of two next generation technology platforms here.